Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

MiNK Therapeutics, Inc. - Common Stock (NQ:INKT)

12.18 -0.12 (-0.98%)
Streaming Delayed Price Updated: 3:59 PM EDT, Sep 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,487
Open 12.00
Bid (Size) 10.96 (9,700)
Ask (Size) 14.00 (1,000)
Prev. Close 12.30
Today's Range 11.70 - 12.46
52wk Range 8.480 - 16.93
Shares Outstanding 34,422,063
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
MiNK Therapeutics (INKT) Q2 2026 Earnings Call Transcript ↗
Net loss narrowed to $3.1 million as Phase 2 trial for agenT-797 advances in Ukraine. 
Via The Motley Fool
Topics Earnings
News headline image
MiNK Therapeutics Q2 Earnings Call Highlights ↗
MiNK Therapeutics (NASDAQ:INKT) said it initiated dosing in a randomized Phase II trial of its allogeneic invariant natural killer T-cell therapy, agenT-797, for patients with acute lung injury and... 
Via MarketBeat
Topics Earnings

Performance

YTD
+9.5%
+9.5%
1 Month
+7.0%
+7.0%
3 Month
+7.7%
+7.7%
6 Month
+26.5%
+26.5%
1 Year
-15.1%
-15.1%

More News

Read More
News headline image
MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics (NASDAQ:INKT) Posts Narrower-Than-Expected Q1 Loss, Advances iNKT Therapy Into Pivotal Testing ↗
Via Chartmill
News headline image
MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK (INKT) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
MiNK (INKT) Q1 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
MiNK Therapeutics Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy
From MiNK Therapeutics
Via GlobeNewswire
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs
From MiNK Therapeutics
Via GlobeNewswire
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
What's going on in today's pre-market session ↗
Via Chartmill
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
Via Chartmill

Frequently Asked Questions

Is MiNK Therapeutics, Inc. - Common Stock publicly traded?
Yes, MiNK Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does MiNK Therapeutics, Inc. - Common Stock trade on?
MiNK Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for MiNK Therapeutics, Inc. - Common Stock?
The ticker symbol for MiNK Therapeutics, Inc. - Common Stock is INKT on the Nasdaq Stock Market
What is the current price of MiNK Therapeutics, Inc. - Common Stock?
The current price of MiNK Therapeutics, Inc. - Common Stock is 12.18
When was MiNK Therapeutics, Inc. - Common Stock last traded?
The last trade of MiNK Therapeutics, Inc. - Common Stock was at 09/25/26 03:59 PM ET
What is the market capitalization of MiNK Therapeutics, Inc. - Common Stock?
The market capitalization of MiNK Therapeutics, Inc. - Common Stock is 419.26M
How many shares of MiNK Therapeutics, Inc. - Common Stock are outstanding?
MiNK Therapeutics, Inc. - Common Stock has 419M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.